Follicular Challenge Test to Predict Response to GnRH Agonist Triggering
- Conditions
- Infertility, Female
- Interventions
- Other: Decapeptyl
- Registration Number
- NCT04973969
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed.
The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.
- Detailed Description
The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol.
Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
-
patients that undergo fertility preservation
- patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS
- Poor ovarian response
- known hypothalamic- pituitary dysfunction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description study group Decapeptyl The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
- Primary Outcome Measures
Name Time Method The response to GnRH triggering One treatment cycle (each cycle is 28 days) for each participant (up to 28 days). LH levels 10-12 hours after decapeptyl trigger, number of mature oocytes
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shamir medical center
🇮🇱Tzrifin, Israel